Interference with RUNX1/ETO leukemogenic function by cell-penetrating peptides targeting the NHR2 oligomerization domain

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Bartel, Yvonne ^a,b   Grez, Manuel ^a   Wichmann, Christian ^a,c  

^a Institute for Biomedical Research   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PENETRATING PEPTIDE; CHIMERIC PROTEIN; HYBRID PROTEIN; POLYPEPTIDE; RECOMBINANT PROTEIN; TAT NHR2 PROTEIN; TRANSCRIPTION FACTOR ETO; TRANSCRIPTION FACTOR RUNX ETO; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; ONCOPROTEIN; TRANSACTIVATOR PROTEIN; PROTEIN BINDING;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; BONE MARROW CULTURE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMOGENESIS; NERVY HOMOLOGY REGION 2; OLIGOMERIZATION; PEPTIDE SYNTHESIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; WESTERN BLOTTING; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; GENETIC TRANSDUCTION; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; PROTEIN MULTIMERIZATION; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE; DRUG EFFECTS;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; HUMANS; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSDUCTION, GENETIC;

EID: 84880147131     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/297692     Document Type: Article

References (57)

1. Döhner K., Döhner H., Molecular characterization of acute myeloid leukemia. Haematologica 2008 93 7 976 982
2. Rosenbauer F., Tenen D. G., Transcription factors in myeloid development: balancing differentiation with transformation. Nature Reviews Immunology 2007 7 2 105 117 2-s2.0-33846622099 10.1038/nri2024
3. Look A. T., Oncogenic transcription factors in the human acute leukemias. Science 1997 278 5340 1059 1064 2-s2.0-0030658039 10.1126/science.278.5340.1059
4. Link K. A., Chou F.-S., Mulloy J. C., Core binding factor at the crossroads: determining the fate of the HSC. Journal of Cellular Physiology 2010 222 1 50 56 2-s2.0-73949157161 10.1002/jcp.21950
5. Melnick A. M., Westendorf J. J., Polinger A., Carlile G. W., Arai S., Ball H. J., Lutterbach B., Hiebert S. W., Licht J. D., The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. Molecular and Cellular Biology 2000 20 6 2075 2086 2-s2.0-0033997967 10.1128/MCB.20.6.2075-2086.2000
6. Peterson L. F., Zhang D.-E., The 8;21 translocation in leukemogenesis. Oncogene 2004 23 24 4255 4262 2-s2.0-2942516037 10.1038/sj.onc.1207727
7. Wang L., Gural A., Sun X.-J., Zhao X., Perna F., Huang G., Hatlen M. A., Vu L., Liu F., Xu H., Asai T., Xu H., Deblasio T., Menendez S., Voza F., Jiang Y., Cole P. A., Zhang J., Melnick A., Roeder R. G., Nimer S. D., The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 2011 333 6043 765 769 2-s2.0-80051470522 10.1126/science.1201662
8. Niebuhr B., Fischer M., Täger M., Cammenga J., Stocking C., Gatekeeper function of the RUNX1 transcription factor in acute leukemia. Blood Cells, Molecules, and Diseases 2008 40 2 211 218 2-s2.0-38949105508 10.1016/j.bcmd.2007.07.018
9. Boissel N., Leroy H., Brethon B., Philippe N., de Botton S., Auvrignon A., Raffoux E., Leblanc T., Thomas X., Hermine O., Quesnel B., Baruchel A., Leverger G., Dombret H., Preudhomme C., Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006 20 6 965 970 2-s2.0-33744487375 10.1038/sj.leu.2404188
10. Paschka P., Marcucci G., Ruppert A. S., Mrózek K., Chen H., Kittles R. A., Vukosavljevic T., Perrotti D., Vardiman J. W., Carroll A. J., Kolitz J. E., Larson R. A., Bloomfield C. D., Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. Journal of Clinical Oncology 2006 24 24 3904 3911 2-s2.0-33748467435 10.1200/JCO.2006.06.9500
11. Hildebrand D., Tiefenbach J., Heinzel T., Grez M., Maurer A. B., Multiple regions of ETO cooperate in transcriptional repression. Journal of Biological Chemistry 2001 276 13 9889 9895 2-s2.0-0035971184 10.1074/jbc.M010582200
12. Lutterbach B., Westendorf J. J., Linggi B., Patten A., Moniwa M., Davie J. R., Huynh K. D., Bardwell V. J., Lavinsky R. M., Rosenfeld M. G., Glass C., Seto E., Hiebert S. W., ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Molecular and Cellular Biology 1998 18 12 7176 7184 2-s2.0-0031724804
13. Lutterbach B., Sun D., Schuetz J., Hiebert S. W., The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. Molecular and Cellular Biology 1998 18 6 3604 3611 2-s2.0-0031844689
14. Zhang J., Hug B. A., Huang E. Y., Chen C. W., Gelmetti V., Maccarana M., Minucci S., Pelicci P. G., Lazar M. A., Oligomerization of ETO is obligatory for corepressor interaction. Molecular and Cellular Biology 2001 21 1 156 163 2-s2.0-0034749349 10.1128/MCB.21.1.156-163.2001
15. Yan M., Ahn E.-Y., Hiebert S. W., Zhang D.-E., RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis. Blood 2009 113 4 883 886 2-s2.0-59649122714 10.1182/blood-2008- 04-153742
16. Kwok C., Zeisig B. B., Qiu J., Dong S., So C. W., Transforming activity of AML1-ETO is independent of CBF β 3 and ETO interaction but requires formation of homo-oligomeric complexes. Proceedings of the National Academy of Sciences of the United States of America 2009 106 8 2853 2858 2-s2.0-62449178451 10.1073/pnas.0810558106
17. Liu Y., Cheney M. D., Gaudet J. J., Chruszcz M., Lukasik S. M., Sugiyama D., Lary J., Cole J., Dauter Z., Minor W., Speck N. A., Bushweller J. H., The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell 2006 9 4 249 260 2-s2.0-33645778328 10.1016/j.ccr.2006.03.012
18. Wichmann C., Becker Y., Chen-Wichmann L., Vogel V., Vojtkova A., Herglotz J., Moore S., Koch J., Lausen J., Mäntele W., Gohlke H., Grez M., Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity. Blood 2010 116 4 603 613 2-s2.0-77956017878 10.1182/blood-2009-10-248047
19. Wichmann C., Chen L., Heinrich M., Baus D., Pfitzner E., Zörnig M., Ottmann O. G., Grez M., Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells. Cancer Research 2007 67 5 2280 2289 2-s2.0-33947277861 10.1158/0008-5472.CAN-06-3360
20. Sloots A., Wels W. S., Recombinant derivatives of the human high-mobility group protein HMGB2 mediate efficient nonviral gene delivery. FEBS Journal 2005 272 16 4221 4236 2-s2.0-23844467776 10.1111/j.1742-4658.2005.04834.x
21. McWhirter J. R., Galasso D. L., Wang J. Y. J., A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Molecular and Cellular Biology 1993 13 12 7587 7595 2-s2.0-0027422977
22. Wadia J. S., Stan R. V., Dowdy S. F., Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nature Medicine 2004 10 3 310 315 2-s2.0-2342595835 10.1038/nm996
23. Rohl C. A., Baldwin R. L., Comparison of nh exchange and circular dichroism as techniques for measuring the parameters of the helix-coil transition in peptides. Biochemistry 1997 36 28 8435 8442 2-s2.0-0030874298 10.1021/bi9706677
24. Mann D. A., Frankel A. D., Endocytosis and targeting of exogenous HIV-1 Tat protein. The EMBO Journal 1991 10 7 1733 1739 2-s2.0-0025797055
25. Tyagi M., Rusnati M., Presta M., Giacca M., Internalization of HIV-1 Tat requires cell surface heparan sulfate proteoglycans. Journal of Biological Chemistry 2001 276 5 3254 3261 2-s2.0-0035793619 10.1074/jbc.M006701200
26. Mai J. C., Shen H., Watkins S. C., Cheng T., Robbins P. D., Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. Journal of Biological Chemistry 2002 277 33 30208 30218 2-s2.0-0037119348
27. Richard J. P., Melikov K., Vives E., Ramos C., Verbeure B., Gait M. J., Chernomordik L. V., Lebleu B., Cell-penetrating peptides: a reevaluation of the mechanism of cellular uptake. Journal of Biological Chemistry 2003 278 1 585 590 2-s2.0-0346460957 10.1074/jbc.M209548200
28. Plank C., Oberhauser B., Mechtler K., Koch C., Wagner E., The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. Journal of Biological Chemistry 1994 269 17 12918 12924 2-s2.0-0028199067
29. Tallman M. S., Gilliland D. G., Rowe J. M., Drug therapy for acute myeloid leukemia. Blood 2005 106 4 1154 1163 2-s2.0-23644455476 10.1182/blood-2005-01-0178
30. Rowe J. M., Tallman M. S., How I treat acute myeloid leukemia. Blood 2010 116 17 3147 3156 2-s2.0-78049392920 10.1182/blood-2010-05-260117
31. Durual S., Rideau A., Ruault-Jungblut S., Cossali D., Beris P., Piguet V., Matthes T., Lentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts. Leukemia 2007 21 5 1050 1059 2-s2.0-34247631683 10.1038/sj.leu.2404645
32. Dunne J., Cullmann C., Ritter M., Soria N. M., Drescher B., Debernardi S., Skoulakis S., Hartmann O., Krause M., Krauter J., Neubauer A., Young B. D., Heidenreich O., siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts. Oncogene 2006 25 45 6067 6078 2-s2.0-33749817426 10.1038/sj.onc.1209638
33. Haferlach T., Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. American Society of Hematology Education Program 2008 400 411 10.1182/asheducation-2008.1.400 2-s2.0-64849100299
34. Cammenga J., Horn S., Bergholz U., Sommer G., Besmer P., Fiedler W., Stocking C., Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood 2005 106 12 3958 3961 2-s2.0-28444437728 10.1182/blood-2005-02-0583
35. Gorre M. E., Mohammed M., Ellwood K., Hsu N., Paquette R., Nagesh Rao P., Sawyers C. L., Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001 293 5531 876 880 2-s2.0-0035800507 10.1126/science.1062538
36. Heidenreich O., Krauter J., Riehle H., Hadwiger P., John M., Heil G., Vornlocher H.-P., Nordheim A., AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 2003 101 8 3157 3163 2-s2.0-0038047685 10.1182/blood-2002-05-1589
37. Zhou Y., Du W., Koretsky T., Bagby G. C., Pang Q., TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice. Blood 2008 112 6 2474 2483 2-s2.0-55249113736 10.1182/blood-2007-12-130211
38. Palermo C. M., Bennett C. A., Winters A. C., Hemenway C. S., The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells. Leukemia Research 2008 32 4 633 642 2-s2.0-39049117344 10.1016/j.leukres.2007. 08.002
39. Essafi M., Baudot A. D., Mouska X., Cassuto J.-P., Ticchioni M., Deckert M., Cell-penetrating TAT-FOXO3 fusion proteins induce apoptotic cell death in leukemic cells. Molecular Cancer Therapeutics 2011 10 1 37 46 2-s2.0-78751556782 10.1158/1535-7163.MCT-10-0482
40. Huang Z., Ji M., Peng Z., Huang S., Xiao Q., Li C., Zeng J., Gao M., Feng W., Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells. Biomedicine and Pharmacotherapy 2011 65 3 183 192 2-s2.0-79959660843 10.1016/j.biopha.2011.02.013
41. Racanicchi S., Maccherani C., Liberatore C., Billi M., Gelmetti V., Panigada M., Rizzo G., Nervi C., Grignani F., Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells. The EMBO Journal 2005 24 6 1232 1242 2-s2.0-17144427653 10.1038/sj.emboj. 7600593
42. Yan M., Kanbe E., Peterson L. F., Boyapati A., Miao Y., Wang Y., Chen I.-M., Chen Z., Rowley J. D., Willman C. L., Zhang D.-E., A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nature Medicine 2006 12 8 945 949 2-s2.0-33746843079 10.1038/nm1443
43. Schwarze S. R., Ho A., Vocero-Akbani A., Dowdy S. F., In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999 285 5433 1569 1572 2-s2.0-0033520487 10.1126/science.285.5433.1569
44. Zorko M., Langel Ü., Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Advanced Drug Delivery Reviews 2005 57 4 529 545 2-s2.0-13844254266 10.1016/j.addr.2004.10.010
45. Pan C., Lu B., Chen H., Bishop C. E., Reprogramming human fibroblasts using HIV-1 TAT recombinant proteins OCT4, SOX2, KLF4 and c-MYC. Molecular Biology Reports 2010 37 4 2117 2124 2-s2.0-77953175260 10.1007/s11033-009-9680-6
46. Gump J. M., Dowdy S. F., TAT transduction: the molecular mechanism and therapeutic prospects. Trends in Molecular Medicine 2007 13 10 443 448 2-s2.0-35248880092 10.1016/j.molmed.2007.08.002
47. Foerg C., Ziegler U., Fernandez-Carneado J., Giralt E., Rennert R., Beck-Sickinger A. G., Merkle H. P., Decoding the entry of two novel cell-penetrating peptides in HeLa cells: lipid raft-mediated endocytosis and endosomal escape. Biochemistry 2005 44 1 72 81 2-s2.0-11844302810 10.1021/bi048330+
48. Shi W., Bartlett J. S., RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Molecular Therapy 2003 7 4 515 525 2-s2.0-0038027345 10.1016/S1525-0016(03)00042-X
49. Drzeniek Z., Stöcker G., Siebertz B., Just U., Schroeder T., Ostertag W., Haubeck H.-D., Heparan sulfate proteoglycan expression is induced during early erythroid differentiation of multipotent hematopoietic stem cells. Blood 1999 93 9 2884 2897 2-s2.0-0344731438
50. Vongchan P., Linhardt R. J., Expression of human liver HSPGs on acute myeloid leukemia. Clinical Immunology 2007 122 2 194 206 2-s2.0-33846109916 10.1016/j.clim.2006.08.017
51. Snyder E. L., Saenz C. C., Denicourt C., Meade B. R., Cui X.-S., Kaplan I. M., Dowdy S. F., Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Research 2005 65 23 10646 10650 2-s2.0-28244484062 10.1158/0008-5472.CAN-05-0118
52. Caron N. J., Quenneville S. P., Tremblay J. P., Endosome disruption enhances the functional nuclear delivery of Tat-fusion proteins. Biochemical and Biophysical Research Communications 2004 319 1 12 20 2-s2.0-2442670068 10.1016/j.bbrc.2004.04.180
53. Tünnemann G., Martin R. M., Haupt S., Patsch C., Edenhofer F., Cardoso M. C., Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. The FASEB Journal 2006 20 11 1775 1784 2-s2.0-33748648777 10.1096/fj.05-5523com
54. Vivès E., Brodin P., Lebleu B., A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. Journal of Biological Chemistry 1997 272 25 16010 16017 2-s2.0-0030904245 10.1074/jbc.272.25.16010
55. Plank C., Zauner W., Wagner E., Application of membrane-active peptides for drug and gene delivery across cellular membranes. Advanced Drug Delivery Reviews 1998 34 1 21 35 2-s2.0-0032487377 10.1016/S0169-409X(98)00005-2
56. Borghouts C., Kunz C., Groner B., Current strategies for the development of peptide-based anti-cancer therapeutics. Journal of Peptide Science 2005 11 11 713 726 2-s2.0-28044454553 10.1002/psc.717
57. So C. W., Cleary M. L., Dimerization: a versatile switch for oncogenesis. Blood 2004 104 4 919 922 2-s2.0-3843124232 10.1182/blood-2004-03-0992